drugset / Trial / NCT06942910

A Study to Investigate the Effects of Zibotentan/Dapagliflozin Combination Compared to Dapagliflozin Alone in Adult Participants With Chronic Kidney Disease and High Proteinuria

NCT06942910 ↗

Phase 2 Active not recruiting 224 enrolled AstraZeneca
RandomizedParallel-groupTriple-blindTreatment

Summary

A Study to Investigate the Effects of Zibotentan/Dapagliflozin Combination Compared to Dapagliflozin Alone in Adult Participants with Chronic Kidney Disease and High Proteinuria

Timeline

Start
2025-05-07
Primary completion
2026-09-26
Completion
2026-09-26

Drugs

EvaluationDrugModalityDoseRoute
Comparator Dapagliflozin Small molecule — Oral
Subject Zibotentan Small molecule — Oral